Pre-surgical immunotherapy was found to show promise in trial for patients with early stage lung cancer, revealed interim results of a large, multicenter trial to be presented at ASCO Annual Meeting.
Participants in the trial had surgically removable NSCLC ranging from stage IB to IIIB. Patients were treated with two cycles of atezolizumab, which blocks the PD-L1 immune checkpoint protein on some cancer cells, then had surgery to remove the lung cancer tissue.
The results to be reported today ...
Pre-surgical immunotherapy was found to show promise in trial for patients with early stage lung cancer, revealed interim results of a large, multicenter trial to be presented at ASCO Annual Meeting.
Participants in the trial had surgically removable NSCLC ranging from stage IB to IIIB. Patients were treated with two cycles of atezolizumab, which blocks the PD-L1 immune checkpoint protein on some cancer cells, then had surgery to remove the lung cancer tissue.
The results to be reported today ...